Jacqueline Flores-Otero1, Kwang H Ahn2, Francheska Delgado-Peraza3, Ken Mackie4, Debra A Kendall5, Guillermo A Yudowski3. 1. 1] Department of Anatomy and Neurobiology, University of Puerto Rico, Medical Sciences Campus, PO Box 365067, San Juan 00936, Puerto Rico [2]. 2. 1] Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut 06269, USA [2]. 3. 1] Department of Anatomy and Neurobiology, University of Puerto Rico, Medical Sciences Campus, PO Box 365067, San Juan 00936, Puerto Rico [2] Institute of Neurobiology, University of Puerto Rico, Medical Sciences Campus, 201 Boulevard del Valle, San Juan 00901, Puerto Rico. 4. Department of Psychological and Brain Sciences, Gill Center for Biomedical Sciences, Indiana University, Bloomington, Indiana 47405, USA. 5. Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut 06269, USA.
Abstract
G protein-coupled receptors (GPCRs) are the major transducers of external stimuli and key therapeutic targets in many pathological conditions. When activated by different ligands, one receptor can elicit multiple signalling cascades that are mediated by G proteins or β-arrestin, a process defined as functional selectivity or ligand bias. However, the dynamic mechanisms underlying β-arrestin signalling remain unknown. Here by studying the cannabinoid receptor 1 (CB1R), we identify ligand-specific endocytic dwell times, that is, the time during which receptors are clustered into clathrin pits together with β-arrestins before endocytosis, as the mechanism controlling β-arrestin signalling. Agonists inducing short endocytic dwell times produce little or no β-arrestin signalling, whereas those eliciting prolonged dwell times induce robust signalling. Remarkably, extending CB1R dwell times by preventing endocytosis substantially increased β-arrestin signalling. These studies reveal how receptor activation translates into β-arrestin signalling and identify a mechanism to control this pathway.
G protein-coupled receptors (GPCRs) are the major transducers of external stimuli and key therapeutic targets in many pathological conditions. When activated by different ligands, one receptor can elicit multiple signalling cascades that are mediated by G proteins or β-arrestin, a process defined as functional selectivity or ligand bias. However, the dynamic mechanisms underlying β-arrestin signalling remain unknown. Here by studying the cannabinoid receptor 1 (CB1R), we identify ligand-specific endocytic dwell times, that is, the time during which receptors are clustered into clathrin pits together with β-arrestins before endocytosis, as the mechanism controlling β-arrestin signalling. Agonists inducing short endocytic dwell times produce little or no β-arrestin signalling, whereas those eliciting prolonged dwell times induce robust signalling. Remarkably, extending CB1R dwell times by preventing endocytosis substantially increased β-arrestin signalling. These studies reveal how receptor activation translates into β-arrestin signalling and identify a mechanism to control this pathway.
G protein-coupled receptors (GPCRs) are the largest family of signal transduction
proteins in the mammalian genome and a major target of therapeutic drugs12. Their signalling includes both canonical pathways mediated by
heterotrimeric G proteins, and non-canonical pathways mediated in part by
β-arrestins34. β-arrestins are multifunctional
scaffold proteins involved in desensitization, clathrin-mediated endocytosis (CME) and
GPCR signalling5678910. Signalling mediated by
β-arrestins is initiated with their recruitment to phosphorylated receptors at
the plasma membrane and they can interact transiently or more permanently with
GPCRs1112131415.Historically, GPCR signalling was considered linear and drug development programmes
focused on the discovery of ligands that would either activate or block receptor
function. However, this simplistic view has gradually evolved along with new
pharmacological data. Today, we know that GPCR signalling can be pluridimensional.
Different agonists acting on the same receptor can activate multiple and sometimes
opposing signalling cascades, a process described as functional selectivity or ligand
bias41012. These agonists may stabilize different active
conformations of the receptor that lead to selective coupling to signalling molecules.
This pluridimensional efficacy holds tremendous therapeutic potential, and great effort
is currently invested in the development of biased agonists that will selectively
activate specific signalling cascades6161718. However, the dynamic
molecular mechanisms underlying functional selectivity remain unknown, and painstaking
pharmacological analysis is currently required to identify and develop more selective
biased ligands, dramatically slowing the pace of drug discovery. To accelerate this
process, a better understanding of the events that simultaneously control multiple
signalling cascades from individual GPCRs is needed.G-protein-signalling cascades have been exquisitely described from the molecular and
mechanistic and, most recently, to the structural level1920. By
contrast, little is known about the mechanistic basis of β-arrestin-mediated
signalling, although β-arrestin-biased ligands are more prevalent than
originally thought and exhibit quite selective downstream outcomes. The current model of
GPCR activation suggests that agonists induce unique receptor conformations and specific
receptor phosphorylation patterns (bar codes) that are linked to β-arrestin
recruitment and biased signalling2122232425. How receptor
activation translates into β-arrestin signalling and the dynamic events
controlling β-arrestin signalling at the molecular level are not clearly
known.Here we combine quantitative live cell total internal reflection fluorescence (TIRF)
microscopy and biochemical analysis to investigate endocytosis and biased signalling of
the cannabinoid receptors 1
(CB1Rs) from endocytic pits. We
demonstrate that agonists produce specific endocytic dwell times, that is, the time
during which receptors are clustered with β-arrestins into endocytic pits
before endocytosis, and dwell time controls β-arrestin-biased signalling.
Prolonged endocytic dwell times produce sustained β-arrestin-biased
signalling. Remarkably, extending dwell times by inhibiting endocytosis significantly
increases β-arrestin signalling.Ligand-specific dwell times have not been previously described and the physiological role
of previously identified endocytic populations of clathrin-coated pits (CCPs) is
currently unknown. These results identify a role for these multiple populations and
describe a mechanism by which agonists control functional selectivity from the
CB1R.
Results
Agonists induce specific CB1R endocytic dwell times
The CB1R is one of the most
abundant receptors in the central nervous system and a key modulator of synaptic
function26. CB1R agonists favour distinct receptor conformations that
can lead to selective association with intracellular signalling pathways, a
mechanism proposed for functional selectivity272829.
Following agonist-induced activation, β-arrestins are recruited to the
plasma membrane to initiate CME3031 and signalling. Given that
CB1Rs and
β-arrestins interact only transiently at the plasma membrane3132, we hypothesized that specific agonist-induced receptor
conformations control the duration of clustering of receptors and
β-arrestins in endocytic pits as a mechanism to influence
β-arrestin signalling.To test this hypothesis, we utilized TIRF microscopy of live cells to investigate
the endocytosis of CB1Rs at
the single pit level33. CB1Rs tagged at the extracellular amino terminus with the
pH-sensitive super-ecliptic phluorin3435 (SEP-CB1R) stably expressed in HEK293 cells
were exposed to saturating concentrations of either the synthetic agonist
WIN 55,212-2 or the
endogenous eicosanoid2-arachidonoylglycerol (2-AG), both considered to be high-efficacy agonists of G
protein activation3637. We found that 10μM
2-AG produced
significantly longer endocytic dwell times, defined as the time receptors are
clustered into endocytic pits before endocytosis, when compared with
5μM WIN 55,212-2
(Fig. 1a–e). Quenching experiments showed
that all SEP-CB1R fluorescence
was rapidly reduced by addition of MES, pH 5.5 to the imaging media. This indicated that the
endocytic clusters analysed in our experiments are indeed at the cell surface
and not dwelling in vesicles below the plasma membrane (Supplementary Fig. 1 and Supplementary Movie 1).
Figure 1
Agonists induce specific endocytic dwell times of the CB1R.
(a) HEK293 cells expressing SEP-CB1Rs before and after 5μM WIN 55,212-2 imaged using TIRF.
Kymographs from the cell surface show individual endocytic events (yellow
rectangle). (b) Normalized fluorescence intensity from the event in
a. s.d. from multiple normalized traces for 5μM
WIN 55,212-2 is
depicted in grey. (c) Representative kymograph showing individual
SEP-CB1Rs endocytic
events in the presence of 10μM 2-AG. (d) Normalized fluorescence intensity from
an endocytic event elicited by 2-AG with s.d. from multiple events in grey. (e)
Box and whiskers plot (median values with min/max range) showing dwell times
of a single endocytic event elicited by 5μM WIN 55,212-2 and 10μM
2-AG (n=336
events per 12 cells and 244 events per 9 cells). (f) Endocytosis
elicited by 5μM WIN
55,212-2 and 10-μM 2-AG was analysed by the decrease
in total surface fluorescence intensity in HEK293 cells by time lapse TIRF
microscopy (n=5 cells per treatment). (g) Dwell times were
analysed for the indicated concentrations of agonist. No statistically
significant difference was observed between concentrations
(n=6–12 cells per condition). (The mean time±s.d.
for 0.1 and 10 μM of WIN 55,212-2 was 106±63
and 117±88 s, respectively. The mean times for 0.1 and
0.5 μM of 2-AG was 177±87 and
159±80 s). (h) Kymograph from a hippocampal
neuron expressing SEP-CB1Rs in the presence of 5 μM
WIN 55,212-2.
(i) Kymograph from a hippocampal neuron incubated with
10 μM 2-AG. (j) Representative traces of normalized
fluorescence from individual endocytic events. (k) Box and whiskers
plot (median values with min/max range) and cumulative probability graphs
from SEP-CB1Rs dwell
times elicited by the indicated agonists in hippocampal neuronal cultures
(n=84 events per 7 cells and 109 events per 10 cells).
Distinct populations of CCPs have been reported at the plasma membrane:
short-lived populations
(τ<20–30 s) associated with
abortive events and long-lived populations
(τ>30–180 s) associated with
productive endocytic events3839. For GPCRs, their structure and
ubiquitination levels have been shown to control the maturation process of
endocytic pits40414243. However, it is not currently known
whether agonists can control the kinetics of endocytic dwell times or whether
the same receptor can adopt multiple dwell times.Thus, next we sought to test whether the variability observed in dwell times
reflects differences in the endocytic efficacy of the agonists or their binding
properties to the receptors. First, we analysed the endocytosis of CB1Rs induced by 5μM
WIN 55,212-2 and
10μM 2-AG, the same
concentrations in the same cells where specific dwell times were observed. TIRF
time-lapse microscopy was performed and surface fluorescence was analysed to
determine the total rate of receptor removal from the cell surface (Fig. 1f). Results indicate that both agonists induced
endocytosis of SEP-CB1R to the
same extent with similar kinetics (τ
=14–18 min; P=0.07 unpaired two-tailed
t-tests throughout the manuscript unless stated). Second, we analysed
whether dwell times were dependent on the concentration of the ligand. We
analysed SEP-CB1R dwell times
at concentrations below and close to the ligand Ki and also at near-saturating
concentrations. The Ki values for WIN
55,212-2 and 2-AG were reported previously as 10–200 and
100–500 nM, respectively, with both agonists having
similar potency and efficacy for GIRK current activation4445464748. Analysis of multiple endocytic events across
several experiments indicated that dwell times were not significantly different
for the concentrations tested for each ligand (Fig. 1g).
These results indicate that the time receptors are clustered into endocytic pits
do not correlate with the endocytic efficacy or agonist concentration,
suggesting a new role for dwell times during the endocytic process.
Ligand-specific dwell times are a conserved mechanism
Previous studies have shown that CB1R function is dramatically sensitive to its cellular
environment and results obtained in heterologous systems do not always replicate
in more complex cells such as primary neuronal cultures4950. To
test whether ligand-specific dwell times are conserved in a more complex
cellular environment, we transfected dissociated hippocampal neurons with
SEP-CB1Rs at DIV
4–5 and performed TIRF microscopy at DIV >15. This lag between
transfection and imaging significantly reduced the expression of
SEP-CB1R towards
physiological levels (Supplementary Fig.
2A,B) and resulted in cellular localization comparable to endogenous
receptors (Supplementary Fig.
2C,D). As observed in HEK293 cells, 5μM WIN 55,212-2 and
10 μM 2-AG elicited dramatically different CB1R dwell times in hippocampal neuronal
cultures (Fig. 1h–k). Dwell times in neurons
were not significantly different from those observed in HEK293 cells for the
same ligand (P=0.35 for 5 μM WIN and P=0.07
for 10 μM 2-AG in HEK versus neurons). These results indicate that
agonists can elicit specific endocytic dwell times that are intrinsic to the
ligand–receptor interaction and not to their cellular
environment.CME has been described as the major mechanism for ligand-induced endocytosis of
the CB1R315152. However, other studies suggested that CB1Rs expressed in heterologous cells
can also colocalize with caveolin-1, and ligand-induced endocytosis can occur in
parallel via CCPs and caveolar endocytosis5354. As different
dwell times could be associated with different endocytic pathways, we
investigated which mechanism mediates ligand-specific dwell times of
CB1Rs. We transiently
transfected fluorescently tagged Ds-Red clathrin or mCherry-caveolin-1 into HEK293 cells stably
expressing SEP-CB1Rs and
analysed individual endocytic events elicited by 5μM WIN 55,212-2. Dual colour simultaneous
TIRF imaging showed that SEP-CB1Rendocytic pits colocalized only with clathrin, and not
with caveolin-1 (Fig. 2a). Kymographs from endocytic movies and intensity
measurements from individual events clearly show that SEP-CB1Rs associate exclusively with Ds-Red
clathrin in the presence of WIN
55,212-2 (Fig. 2b,c). Next, we elicited
endocytosis with 10μM 2-AG. Single frames from endocytic movies and their
kymographs show that SEP-CB1R
endocytosis is again associated with the recruitment of clathrin and not
caveolin-1 (Fig. 2d,e). Fluorescence intensities from individual
SEP-CB1R endocytic events
failed to associate with mCherry-caveolin-1 (Fig. 2f). Colocalization
analysis from individual endocytic events across multiple experiments indicated
that CB1Rs were highly
colocalized with clathrin (Pearson’s=0.5–0.55) when
compared with caveolin
(Pearson’s=0.07−0.05) for both agonists (Fig. 2g,h), strongly suggesting that CME is the endocytic mechanism
underlying ligand-specific dwell times.
Figure 2
Agonists control the maturation process of CB1R clathrin-coated pits.
(a) HEK293 cells co-expressing SEP-CB1Rs and DsRed-clathrin (top) or mCherry-caveolin-1 (bottom) incubated with
5μM WIN
55,212-2 and imaged under TIRF microscopy. Single frames
show overlay after 5 min of incubation. (b) Kymographs
showing individual SEP-CB1R endocytic event with clathrin (top, yellow traces)
and caveolin-1 (bottom).
(c) Representative normalized fluorescence intensity scan from
the overlay of SEP-CB1Rs
and DsRed-clathrin. (d) HEK293 cells expressing SEP-CB1Rs and either DsRed-clathrin
(top) or mCherry-caveolin-1 (bottom) were incubated with 10μM
2-AG. Single frames
after 5 min show the overlay. (e) Kymographs showing
individual SEP-CB1R
endocytic events with clathrin (top, yellow traces) and
mCherry-caveolin-1
(bottom). (f) Representative fluorescence intensity trace from an
individual SEP-CB1R
endocytic event showing no colocalization with mCherry-caveolin-1. (g)
Colocalization was analysed in multiple cells 5 min after
treatments between CB1Rs
and clathrin or CB1Rs and
caveolin-1
(n=5–7 cells, error bars represent s.e.m. from multiple
analyses). (h) Colocalization analysis after a 5-min treatment with
10μM 2-AG
between SEP-CB1Rs and
DsRed-clathrin or mCherry-caveolin-1 (n=6–9 cells, error
represents s.e.m. from multiple analyses). (i) Clathrin-coated pit
dwell times were analysed in HEK cells expressing only Ds-Red-clathrin under
basal conditions or in the presence of the indicated ligands. (j) The
mean intensity from the initial 20 s from events elicited with
5μM WIN
55,212-2, black shows the mean and grey s.d. (n=50
events). (k) The mean intensity from endocytic events elicited with
10μM 2-AG
(n=70 events). (l) Box and whiskers analysis comparing
normalized intensities from j,k at 20 s (left) and
40 s (right) after event onset (P=0.46 and P=0.29,
respectively, plot indicates the median values and min/max range).
As modulation of dwell times could be mediated by the presence of CB1Rs or by a non-CB1R-mediated effect of the agonist, we
analysed the dwell times of CCPs in HEK293 cells transfected with fluorescently
tagged Ds-Red clathrin in the absence of SEP-CB1Rs. Dwell times were investigated in untreated cells or
in the presence of 5μM WIN55,212-2 and 10μM 2-AG. Our results showed no significant
difference in dwell times between untreated control and treated cells in the
absence of SEP-CB1R (Fig. 2i). Importantly, dwell times obtained from CCPs
closely resemble dwell times previously reported in the literature555657.CCPs traverse distinct steps during their lifetime before removal from the cell
surface. Major events are assembly or pit initiation, maturation and final
separation from the cell surface55. Growing evidence suggests
that these steps can be regulated by lipid kinases and phosphatases that control
the formation and maturation processes of CCPs585960. To
investigate which of these steps agonists modulate, we compared the changes in
fluorescence intensity during the assembly and maturation processes of
individual SEP-CB1R endocytic
pits with similar kinetics. Fluorescence intensity traces from individual events
were normalized to their maximum and compared for WIN 55,212-2 and 2-AG. Analysis of multiple events
indicated that maximum intensities (maximum number of receptors) were reached
with similar kinetics for both agonists, with no significant difference observed
during the assembly phase (Fig. 2j–l,
τ ~24 s). This suggests that the
recruitment of receptors into individual endocytic pits occurs with similar
kinetics; however, once the coated pits reach their maximum number of receptors
(at maximum intensity), pits linger for variable periods of time depending on
the ligand that activated the receptor. As we cannot identify changes at the
single receptor level, we cannot rule out the possibility that individual
receptors move in and out from single pits during dwell times as described for
other cargoes57.β-arrestins bind to activated GPCRs to initiate the endocytic
process11121314. As agonists can determine the time
receptors are clustered into endocytic pits with β-arrestins, we
hypothesized that this regulation could mediate β-arrestin signalling.
To test this hypothesis, first we investigated the recruitment kinetics of
β-arrestin-1
into CB1Rs CCPs. We have
previously shown that β-arrestin-1 mediates CB1R activation of ERK1/2 (ref. 61). Cells stably expressing SEP-CB1Rs were transfected with red
fluorescent protein (RFP)-tagged β-arrestin-1 and incubated with either
5μM WIN 55,212-2 or
10μM 2-AG and imaged
under TIRF microscopy. Upon ligand incubation, β-arrestin-1 was rapidly
recruited to the plasma membrane and into individual endocytic pits as depicted
in kymographs (Fig. 3a and Supplementary Movie 2). Normalized individual
fluorescence traces indicated that β-arrestin-1 was recruited into SEP-CB1Rendocytic pits and remained present
throughout the endocytic process (Fig. 3b). As observed
with SEP-CB1Rs, 2-AG elicited longer β-arrestin-1 dwell times when
compared with WIN 55,212-2
(Fig. 3c,d). Analysis of multiple experiments from
cells co-expressing RFP-β-arrestin-1 and SEP-CB1Rs showed a significant increase in
the dwell time of β-arrestins in the presence of 2-AG (Fig. 3e,f).
This increase in dwell time was comparable to those observed with
SEP-CB1R alone, suggesting
that the overexpression of RFP-β-arrestin did not have a deleterious
effect on the endocytic process (Figs 1e and 3e). Correlation analysis between dwell times of
CB1R and β-arrestin-1 from the same
endocytic events indicated that both proteins are recruited and retained at CCPs
with identical ligand-dependent kinetics (Fig. 3g,h).
Figure 3
β-arrestin-1 is
recruited and retained into CB1R CCPs with ligand-specific kinetics.
(a) HEK293 cells co-expressing SEP-CB1R and mRFP-β-arrestin-1 were incubated with 5μM
WIN 55,212-2 and
analysed under dual-colour TIRF microscopy. Representative kymograph showing
individual SEP-CB1R
events colocalizing with mRFP-β-arrestin-1. (b) Individual normalized
fluorescence intensity from SEP-CB1Rs and β-arrestin-1 during the endocytic event from
a (yellow rectangle). (c) Representative kymograph from
HEK293 cells expressing SEP-CB1R and mRFP-β-arrestin-1 in the presence of 10μM
2-AG. Individual
SEP-CB1R endocytic
events colocalize with β-arrestin-1. (d) Normalized
fluorescence intensity from SEP-CB1Rs and mRFP-β-arrestin-1 from c (yellow rectangle).
(e) Box and whiskers plot showing β-arrestin 1 dwell times
into CCPs elicited by 5μM WIN
55,212-2 and 10μM 2-AG, n=342 events per 19
cells and 378 events per 21 cells (plot indicates the median values with
min/max range). (f) Cumulative probability from β-arrestin 1 dwell times
for 5μM WIN
55,212-2 and 10μM 2-AG. (g) Correlation
between β-arrestin
1 dwell times and SEP-CB1R dwell times from the same endocytic event when
elicited by 5μM WIN
55,212-2 (P<0.0001; n=305 endocytic
events). (h) Correlation between β-arrestin 1 dwell times and SEP-CB1R dwell times from the same
endocytic event when elicited by 5μM 2-AG (P<0.0001;
n=197 endocytic events).
β-arrestin-2 has
previously been shown to be involved in CB1R internalization28. To investigate the
recruitment kinetics of β-arrestin-2 to CB1R CCPs, HEK293 cells stably expressing SEP-CB1Rs were transfected with RFP-tagged
β-arrestin-2.
Recruitment was initiated by either 5μM WIN 55,212-2 or 10μM
2-AG. As previously
observed with β-arrestin-1, β-arrestin-2 was efficiently recruited to the
plasma membrane and into individual endocytic pits (Fig.
4a,b). Analysis of β-arrestin-2 dwell times at CCPs showed identical
ligand-specific kinetics to those observed before (Figs
3e,f and 4c,d). These data show that both
β-arrestins can be recruited and retained into CB1R-CCPs with ligand-dependent
specificity.
Figure 4
β-arrestin-2 is
recruited and retained into CB1R CCPs with ligand-specific kinetics.
(a) HEK293 cells co-expressing SEP-CB1R and mRFP-β-arrestin-2 were incubated with 5μM
WIN 55,212-2 and
analysed under dual-colour TIRF microscopy. Representative kymograph depicts
an individual endocytic event and the colocalization between
SEP-CB1R and
mRFP-β-arrestin-2. (b) Individual normalized
fluorescence intensity from SEP-CB1R and β-arrestin-2. (c) Box and whiskers plot
(the median values and min/max range) showing β-arrestin-2 dwell times
(n=304 events per 21 cells and 321 events per 15 cells).
(d) Cumulative probability for β-arrestin 2 dwell times
in the presence of 5μM WIN
55,212-2 and 10μM 2-AG.
2-AG signals through G
proteins and β-arrestin-1
To test the hypothesis that prolonged dwell times influence β-arrestin
signalling, we investigated ERK1/2 phosphorylation in response to WIN 55,212-2 and 2-AG along with the agonists
CP55940 and its
ago-allosteric modulator ORG27569 for comparison. We have previously demonstrated
that ERK1/2 can be activated
via CB1Rs in both a
G-protein-dependent and G-protein-independent manner286162.
All four compounds induced ERK1/2 phosphorylation that peaked at 5 min
(Fig. 5a,b). Most strikingly, 2-AG treatment resulted in sustained
phosphorylation that was still substantial at 15 min (Fig. 5a bottom and Fig. 5b), while the
phosphorylation elicited by CP55940, ORG27569 and WIN
55,212-2 drastically decreases after 5 min.
Figure 5
CB1R/β-arrestin-1 mediates the
activation of ERK1/2 by
2-AG.
(a) HEK293 cells expressing SEP-CB1Rs were exposed to 10μM CP55940, ORG27569, WIN 55212-2 and 2-AG for 5, 10 and
15 min. Cell lysates were analysed using western blots with
phospho-ERK1/2
(p-ERK1/2) or total
ERK1/2. (b)
Quantified time course in a showing ERK1/2 phosphorylation levels
induced by 10 μM of each compound. (c) HEK293
cells expressing SEP-CB1Rs were exposed to 10μM CP55940, ORG27569, WIN 55212-2 and 2-AG for 5, 10 and
15 min with PTX pre-treatment, respectively. (d)
Quantified time course in c showing ERK1/2 phosphorylation levels from
cells pretreated with PTX. (e,g,i,k) HEK293
cells co-expressing SEP-CB1R and either control (e), β-arrestin-1 (g),
β-arrestin-2 (i) siRNAs or
β-arrestin-2 siRNA with PTX pretreatment
(k) were exposed to 10 μM of CP55940, ORG27569, WIN 55212-2 and 2-AG, respectively, as indicated.
(f,h,j,l). Graphs in
f,h,j,l provide the quantified ERK1/2 phosphorylation levels
induced by 10 μM of each compound as shown in
e,g,i,k. Data represent the
mean±s.e.m. of at least three independent experiments.
To establish specificity, HEK293 cells lacking CB1Rs did not show changes in
ERK1/2 phosphorylation
upon treatment of each of the four compounds, indicating that the
phosphorylation pattern shown in Fig. 5a is CB1-mediated (Supplementary Fig. 3D). We also analysed
whether ORG27569 can induce
endocytic events. Interestingly, 10μM ORG27569 elicited a very small number
of endocytic events reflecting its ago-allosteric function. Remarkably, the
dwell times elicited by ORG27569 were statistically indistinguishable from those
observed with 2-AG (Supplementary Fig. 3C).To evaluate the involvement of Gi/o proteins in ERK1/2 phosphorylation, we treated
cells expressing SEP-CB1Rs
with pertussis toxin (PTX). Consistent with previous findings56,
PTX attenuated CP55940-induced ERK1/2 phosphorylation, while it showed no effect on
ORG27569-induced
phosphorylation (Fig. 5c top). PTX treatment also
abolished WIN
55,212-2-induced ERK1/2 phosphorylation. Strikingly, PTX treatment inhibited
2-AG-induced
ERK1/2 phosphorylation at
the early time point (5 min), but not the later time points (10 and
15 min; Fig. 5c bottom and 5d). This suggests
that 2-AG induces
ERK1/2 activation via
multiple pathways and only activation at the early time point is mediated by Gi
proteins.To test whether β-arrestins mediate 2-AG-induced ERK1/2 phosphorylation at later time points, we used
silencing technology to reduce the expression of endogenous β-arrestin-1 and
β-arrestin-2.
Co-transfection with SEP-CB1Rs and negative control short interfering RNA (siRNA)
exhibited a similar pattern of ERK1/2 phosphorylation (Fig. 5e,f) to
controls (Fig. 5b). Consistent with previous data28, Fig. 5g shows that while the reduced
expression of β-arrestin-1 exhibited little effect on
CP55940-induced
ERK1/2 phosphorylation,
it substantially abrogated ORG27569-induced ERK1/2 phosphorylation, indicating that this phosphorylation
is mediated by β-arrestin-1. WIN 55,212-2-induced ERK1/2 phosphorylation remained unaffected with the reduced
expression of β-arrestin-1. Most strikingly, silencing
β-arrestin-1
resulted in a significant decrease in the level of phosphorylation induced by
2-AG at the later time
points (10 and 15 min) without affecting its phosphorylation at the
5-min time point (Fig. 5g,h). The effectiveness of
isoform-specific silencing of β-arrestin 1 and 2 was confirmed (Supplementary Fig. 3E). Taken together, these
results show that 2-AG
induces a maximal Gi/o-mediated ERK1/2 phosphorylation at 5 min followed by a
sustained ERK1/2 activation
at the later time points (10 and 15 min) mediated by β-arrestin-1 providing the
first reported case of canonical and non-canonical signalling pathways induced
by the endogenous agonist 2-AG via CB1R.Reduction of β-arrestin-2 using siRNA did not have a
substantial effect on CP55940-, ORG27569- and WIN
55,212-2-induced ERK1/2 phosphorylation when compared with controls (Fig. 5i), although these agonists resulted in a small but
sustained level of ERK1/2
phosphorylation at the later time points (10 and 15 min) compared
with those shown by control siRNA transfection (Fig. 5j).
This may reflect a need for β-arrestin-2 for internalization3132 and reduced internalization may allow for extended Gi/o
signalling. To test this possibility, we treated cells expressing
SEP-CB1Rs with PTX. PTX
treatment inhibited CP55940-
and WIN 55,212-2-induced
extended ERK phosphorylation suggesting that the extended ERK1/2 phosphorylation is Gi-mediated
(Fig. 5k,l). In contrast, the substantially sustained
levels of ERK1/2
phosphorylation at the later time points induced by 2-AG treatment (Fig.
5e bottom) was diminished to a level similar to that of CP55940, ORG27569 or WIN 55,212-2 treatment. It is possible
that the reduced expression of β-arrestin-2 results in inhibition of CCP
formation, thus abrogating the β-arrestin signalling that occurs in
endocytic pits but prolonging ongoing Gi/o signalling. Interestingly, PTX
treatment further inhibited 2-AG-induced ERK phosphorylation (Fig.
5k) suggesting that the diminished level of phosphorylation resulting
from β-arrestin-2
knockdown is Gi-mediated.
Extension of dwell times enhances β-arrestin
signalling
To directly test the hypothesis that dwell times dictate
β-arrestin-mediated ERK1/2 signalling, we pre-treated cells with the dynamin
inhibitor dyngo-4a. Inhibition of endocytosis dramatically prolonged
SEP-CB1R dwell times
throughout the imaging sessions (Fig. 6a) and, according
to our model, it should enhance β-arrestin-mediated signalling. Since
2-AG exhibited a
significantly longer endocytic dwell time than WIN 55,212-2 (Fig.
1e) and sustained β-arrestin-mediated ERK1/2 signalling (Fig.
5), the effect of prolonging the endocytic dwell time on
2-AG-induced
ERK1/2 phosphorylation
was evaluated up to 60 min. Figure 6b shows
that 2-AG treatment (no
dyngo-4a) exhibited a sustained phosphorylation pattern of ERK1/2 up to 15 min, while
the phosphorylation by WIN
55,212-2 drastically decreases after the 5-min peaks.
Strikingly, pre-treatment with dyngo-4a resulted not only in an extension but
also in an increase in 2-AG-induced ERK1/2 phosphorylation (Fig. 6b,c).
WIN 55,212-2 treatment
showed essentially no increase in ERK1/2 phosphorylation in the presence of dyngo-4a, except
for a small increase at later time points (45 and 60 min). One
possible explanation is that prolonging dwell times results in increased
interactions with either G protein or β-arrestin for ERK1/2 signaling.
Figure 6
CB1R dwell times control
β-arrestin signalling.
(a) HEK293 cells expressing SEP-CB1R were preincubated with 30μM dyngo-4a and
imaged under TIRF before and after bath application of 10μM
WIN55212-2.
Representative kymograph shows prolonged SEP-CB1R dwell times in the presence of
dyngo-4a. (b) HEK293 cells expressing SEP-CB1R were pre-incubated with
30μM dyngo-4a before exposure to agonists and compared with no
dyngo-4a treatment. (c) Graph provides the quantified ERK1/2 phosphorylation induced by
10 μM of each compound shown in b. Data are
expressed as a percentage of the level of phosphorylation at
5 min for each compound without dyngo-4a pre-treatment.
(d) HEK293 cells expressing SEP-CB1Rs with and without dyngo-4a pretreatment were
exposed to 10μM 2-AG as indicated with PTX pre-treatment. (e)
HEK293 cells co-expressing SEP-CB1R and β-arrestin-1 siRNAs with and without dyngo-4a
pretreatment were exposed to 10μM 2-AG as indicated. (f)
Quantified time course in d,e showing ERK1/2 phosphorylation levels
induced by 10μM 2-AG for 5, 15, 30, 45 and 60 min for cells
either pre-treated with PTX or co-transfected with β-arrestin-1 siRNA.
(g) HEK293 cells expressing SEP-CB1R were treated with PTX (or no
PTX as a control), and then incubated with 30μM dyngo-4a before
subsequent exposure to WIN
55,212-2. (h) Graph provides the quantified
ERK1/2
phosphorylation induced by 10μM WIN 55,212-2 in the absence of PTX
treatment shown in g. (i) HEK293 cells expressing
SEP-CB1R with or
without dominant-negative dynamin
2 K44A were exposed to agonists. (j) Graph
provides the quantified ERK1/2 phosphorylation induced by
10 μM of each compound shown in i. All data are
expressed as a percentage of the level of phosphorylation at
5 min for 2-AG
without dyngo-4a pre-treatment and represent the mean±s.e.m. of at
least three independent experiments.
Finally, to determine whether the increase in ERK1/2 phosphorylation by 2-AG in the presence of dyngo-4a was
mediated by β-arrestins, cells were incubated with PTX or
co-transfected with β-arrestin-1 siRNA. Figure
6d shows that preincubation with PTX inhibited 2-AG-induced ERK1/2 phosphorylation at
5 min but had no effect during the later time points between 15 and
60 min. In contrast, silencing of β-arrestin-1 expression resulted in a substantial
decrease in the level of phosphorylation induced by 2-AG at the later time points between
15 and 60 min without affecting its phosphorylation at the 5-min time
point (Fig. 6e,f). To investigate whether prolonging
endocytic dwell times with dyngo-4a treatment results in an increase in
ERK1/2 phosphorylation in
the absence of Gi protein, we treated PTX-pretreated HEK293 cells expressing
SEP-CB1R with dyngo-4a.
WIN 55,212-2 treatment
failed to show any increase in ERK1/2 phosphorylation in the presence of dyngo-4a and PTX
compared with those without PTX treatment (Fig. 6g,h).
These data suggest that WIN
55,212-2 promotes the CB1 conformation that couples to Gi but not to
β-arrestinTo further confirm the correlation between longer endocytic dwell times and
extended β-arrestin signalling induced by dyngo-4a, we expressed a
dynamin
2-dominant-negative mutant. Expression of the dominant-negative
dynamin also substantially extended ERK1/2 phosphorylation, similarly to dyngo-4a treatment,
upon 2-AG treatment (Fig. 6i top and Fig. 6j). In contrast,
WIN 55,212-2 treatment
showed essentially no increase in ERK1/2 phosphorylation upon co-expression of the
dynamin
2-dominant-negative mutant (Fig. 6i
bottom), also comparable to dyngo-4a treatment. Taken together, these results
show that prolonging CB1R
dwell times by the dynamin inhibitor dyngo-4a or expression of the
dominant-negative dynamin 2
significantly increased 2-AG-induced activation of ERK1/2 mediated by β-arrestin-1.
Discussion
Our results provide insights into the molecular events underlying functional
selectivity during β-arrestin signalling from the CB1R. We demonstrate that agonists modulate
how long receptors interact with β-arrestins in endocytic pits at the cell
surface to control the extent of β-arrestin signalling. The synthetic
agonist WIN 55,212-2 elicits
short endocytic dwell times and activates mainly G proteins (G protein bias), while
the endogenous agonist 2-AG
elicits prolonged dwell times and promotes short-term G protein and longer-term
β-arrestin signalling (as expected for a more balanced ligand). Ligand
specificity of dwell time was identical in hippocampal neurons, while siRNA
silencing technology and pertussis toxin treatment confirmed that activation of
ERK1/2 was indeed selectively
mediated by β-arrestin-1. β-arrestin-2 was also recruited to CCPs with similar
kinetics, likely mediating receptor internalization based on earlier work. To
further challenge our model, chemical and genetic extension of receptor dwell times
resulted in a significant increase in β-arrestin-1-mediated signalling.It is interesting that, although WIN
55,212-2 induces CB1R endocytosis via β-arrestin32, it
failed to show β-arrestin-mediated signalling. Our results using PTX
treatment and β-arrestin siRNA indicate that WIN 55,212-2-induced ERK1/2 phosphorylation is
G-protein-mediated. In previous studies, we demonstrated that, although
β-arrestin-biased ORG27569 and G protein-biased CP55940 (ref. 28) and WIN
55,212-2 (ref. 32) induced
β-arrestin
2-mediated endocytosis, only ORG27569, but not CP55940-induced c-Src activation in a
β-arrestin-dependent manner. Interestingly, Gyombolai et al.32 also showed no significant interaction of CB1R with β-arrestin-1 upon WIN 55,212-2 treatment, which is the key
isoform for signalling for CB1R28. Collectively, while we cannot absolutely
rule out the possibility that WIN
55,212-2 treatment induces other CB1R signalling cascades via
β-arrestin, these data suggest that WIN55212-2 is a G protein-biased agonist and requires
β-arrestin-2 for
endocytosis only.How are ligand-specific dwell times generated and how do they control signalling? As
the CB1R is a member of the class
A family and the interaction with β-arrestins occurs transiently at the
plasma membrane before endocytosis, modulation of β-arrestin signalling
would occur during the formation of CCPs and before their removal from the cell
surface3132. We hypothesize that endocytic agonists induce
specific phosphorylation patterns or bar codes in the intracellular domain of the
receptor, stabilizing specific conformations that promote differential interactions
with β-arrestins at the plasma membrane while initiating signalling232463. In this case, 2-AG would generate a receptor conformation and consequent
phosphorylation bar code that will translate into a specific and prolonged
interaction between receptor and β-arrestin-1. How can β-arrestins activate
specific signalling cascades during the endocytic process? This requires a dynamic
mechanism that could link distinct signalling molecules to correct receptor/arrestin
combinations. The extended contact during prolonged dwell times could provide the
necessary time for all the signalling components to be effectively recruited to
β-arrestin-1 and
activated. Although both WIN
55,212-2 and 2-AG induced the receptor endocytosis with a similar kinetics,
2-AG treatment resulted in
prolonged β-arrestin-mediated signalling and endocytic dwell times. It
will be interesting to investigate the kinetics of interaction between CB1R and each β-arrestin
isoform15 and determine whether subsequent endosome signalling
also occurs6465. This study identifies the mechanisms by which
CB1Rs controls
β-arrestin signalling, and suggests modulation of receptor trafficking as
a novel therapeutic strategy to control GPCR function.
Methods
Cell cultures and transfection
Humanembryonic kidney cells (HEK293 cells) were obtained from ATCC (Manassas,
VA, USA). They were maintained in complete growth Dulbecco’s modified
Eagle’s medium (DMEM), supplemented with 10% fetal bovine serum
(FBS), 0.1% penicillin–streptomycin and 2 mM glutamine (all from Life Technologies,
Grand Island, NY, USA). Embryonic day 14 rat hippocampal tissue was obtained
from BrainBits LLC (Springfield, IL, USA). Twenty-four hours post arrival,
hippocampal tissue was dissociated in 1 × trypsin (Life Technologies)
for 15 min at 37 °C before 4 ml of
supplemented DMEM was added for 5 min at room temperature.
Hippocampal neurons were triturated using a glass pipette. Cultures of
250,000 cells per 35-mm petri dish were plated and incubated 5 days
before transfection. Before seeding, glass coverslips (30 mm) were
coated with poly-D-Lysine and after detection of neuronal attachment, culture
media was replaced for Neurobasal media (Life technologies). HEK293 cell and
hippocampal neurons were transfected with 3–4 μg
of SEP-CB1R cDNA (gift from
Andrew Irving, University of Dundee and characterized here34 or
co-transfected with 2–3 μg of SEP-CB1R: Ds-Red-Clathrin (CCP) light chain
cDNAs; SEPCB1:
mCherry-Caveolae cDNAs (gift from Mark von Zastrow, University of California,
San Francisco) or SEP-CB1:
RFP-β-Arrestin2
cDNAs (kindly provided by Dr. Ken Mackie). HEK293 cells were transfected using
Effectene following the manufacturer’s protocol (Qiagen, Valencia,
CA, USA), after DIV2-3 post culture. Hippocampal neurons were transfected using
Lipofectamine 2000 (Life Technologies) according to the
manufacturer’s protocol after DIV5 post culture. CB1R ligands such as WIN 55212-2 and 2-AG, 2-AG were purchased from Tocris (Tocris
Bioscience, Bristol, UK).
β-arrestin siRNA and dominant-negative dynamin
experiments
HEK293 cells (ATCC) were maintained in DMEM supplemented with 10% FBS and
3.5 mg ml−l
glucose at
37 °C in 5% CO2. Transfection was carried out
using lipofectamine (Life Technologies) according to the
manufacturer’s instructions. Twenty-four hours post transfection,
cells were washed and incubated for an additional 18 h in serum-free
growth media. siRNA (Qiagen) transfection was carried out as previously
described28. Briefly, HEK293 cells that were
40–50% confluent in a six-well plate were transfected with the
plasmid encoding ratCB1 and
2.6 mg of siRNA (Qiagen) sequences targeting β-arrestin 1, β-arrestin 2 or non-silencing
RNA duplex for control. Silencing of β-arrestin 1 and β-arrestin 2 expression was
assessed by immunoblotting using anti-β-arrestin 1 (1:2,000; EMD Millipore, Billerica,
MA, USA) and anti-β-arrestin
2 (1:1,000; Novus Biologicals, Littleton, CO, USA)
antibodies, respectively. For the dominant-negative dynamin 2 experiments, the
dynamin 2K44A mutant was
generated by site-directed mutagenesis (Stratagene, La Jolla, CA, USA) using the
humandynamin 2 cloned into
the pmCherryN1 vector (Addgene, Cambridge, MA, USA). HEK293 cells were
co-transfected with SEP-CB1R
and K44Adynamin 1-mCherry
cDNAs using lipofectamine described above.
Immunoblotting studies
Cells expressing HA-tagged ratCB1 receptor were washed twice and exposed to either 0.5 or
10 μM of the CB1 agonists CP55940, WIN
55212-2 or 2-AG, or the allosteric modulator ORG27569 for 5, 10 and
15 min. To observe the effect of PTX on ERK1/2 phosphorylation, cells were
pretreated with 10 ng ml−l for
16 h at 37 °C. In Dyngo-4a experiments to inhibit
dynamin and endocytosis, cells were incubated with 30 μM
Dyngo-4a for 15 min before agonist treatment. Cells were exposed to
10μM 2-AG or
WIN55212-2 for 5, 15, 30,
45 and 60 min, washed with ice-cold phosphate-buffered saline (PBS)
and lysed in ice-cold lysis buffer consisting of 150 mM NaCl, 1.0% IGEPAL CA-630, 0.5%
sodium deoxycholate, 0.1%
SDS, 50 mM
Tris, pH 7.5 and a
protease inhibitor cocktail 4-(2-aminoethyl)benzenesulfonyl fluoride, pepstatin A, E-64, bestatin, leupeptin and aprotinin; Sigma, St
Louis, MO, USA). Solubilized cell extracts were centrifuged at
18,500 g for 15 min at
4 °C. The supernatant was transferred to a fresh tube and
heated at 95 °C for 3 min. In all,
15 μg of total proteins were resolved with
SDS–PAGE gel electrophoresis in 10% gels and transferred onto
polyvinylidene fluoride membrane. After incubating with blocking reagent (Fisher
Scientific, Pittsburgh, PA, USA), the membrane was incubated for 1 h
at room temperature with the primary antibody (1:3,000 phospho-p44/42 and p44/42 antibodies; Cell Signaling
Technology, Danvers, MA, USA). After extensive washing with PBS, the membrane
was incubated with anti-rabbit peroxidase-conjugated secondary antibody
(1:5,000; Cell Signaling Technology) for 45 min at room temperature.
The specific immunoreactivity was visualized using the SuperSignal West Femto
Chemiluminescent Substrate System (Thermo Fisher Scientific, Rockford, IL, USA)
according to the manufacturer’s instructions. Immunoreactive bands of
phospho-ERK1/2 were
quantified by densitometric analysis using the ImageJ programme ( http://rsb.info.nih.gov/ij/) and
normalized to the intensity of total-ERK1/2. Data are expressed as a fold increase above the
basal level of phosphorylation. Uncropped blots of the most important western
blots are included in the Supplementary
Fig. 4.
TIRF microscopy
TIRFM was performed in HEK293 cells and hippocampal neurons on DIV5 and DIV12,
respectively, utilizing a Motorized Nikon Ti-E inverted microscope with a
CFI-Apo × 100 1.49 oil TIRF objective lens with colour correction and a
motorized stage with perfect focus(Melville, NY, USA). Light sources were 488-
and 561-nm Coherent sapphire lasers (Coherent Inc., Santa Clara, CA, USA) with
50 and 100 mW, respectively. The microscope was coupled to an
iXonEM+DU897 back illuminated EMCCD camera (Andor, Belfast, UK). Imaging
settings were kept constant throughout our imaging: readout speed:
10 Hz, exposure time: 100 ms every 3 s, EM gain
300, binning: 1 × 1, image: 512 × 512, BitDepth=14 bits,
temperature: −75 and laser power: 10%. Cells were kept at
37 °C with a Stable Z stage and objective warmer (Bioptechs,
Butler, PA, USA).Cells were gently rinsed three times with OptiMem supplemented with
20 mM HEPES (Life
Technologies) and kept in the incubator for 10–30 min to
acclimate before imaging. TIRFM recording was conducted in the same imaging
media for 1–3 min under basal condition (without any
treatment) and was followed by bath application of selected ligand using a
custom-built perfusion chamber. Total time of live-imaging visualization and
recording was less than 30 min.
Image processing and analysis
Analysis of SEP-CB1,
Ds-Red-CCP, mCherry-Caveolae or RFP-β-Arrestin2 endocytic events was performed as
described before336667. Briefly, raw images were first
background-subtracted and flat field-corrected33. Individual
endocytic events were quantified by an observer blinded to experimental details,
multiple times manually and using the particle tracking algorithm
two-dimensional spot tracker68. Individual event location, time
and fluorescence profile were logged and recorded. Individual endocytic events
were identified and scored according to the following criteria: (1) individual
events appeared and disappeared within the time series; (2) endocytic events
displayed limited movement in the x and y axes as described for
clathrin endocytic pits during their maturation phase385569;
and (3) the events did not collide or merge with other structures. Dwell times
were calculated as the time between the first frame where spot tracker detected
an event above background fluorescence levels and the last. As the fluorescence
from individual events can fluctuate and the algorithm from the tracking
software can misinterpret endocytic events, we manually verify all individual
events after automated analysis. Figures of endocytic events are shown through
orthogonal views of image series as kymographs. In the kymographs, horizontal
lines illustrate the receptor’s endocytic event. The beginning of the
horizontal line represents the time at which the receptor is at the surface of
the membrane, the end of the horizontal line represents the time at which the
receptor is internalized and the length of the horizontal line refers to the
duration of the receptor at the cell surface before endocytosis occurs
(endocytic lifetime or dwell time). Endocytic time constants from bulk
endocytosis (Fig. 1f) where determined by fitting raw
fluorescence data to a single exponential decay function± s.d. All
other data are expressed as means±s.e.m unless stated. Unpaired
two-tailed Student’s t-tests were used to test for statistical
significance. Statistical analyses including Pearson’s correlation
between dwell times were calculated utilizing the GraphPad Prism Software (La
Jolla, CA, USA). Box and whiskers plot represent minimum and maximum values, the
box extends from 25 to 75% with the mean value.
Author contributions
G.A.Y. conceived and supervised the project. G.A.Y., J.F.-O., K.H.A., F.D.-P.
acquired data. J.F.-O., K.H.A., F.D.-P., K.M., D.A.K. and G.A.Y. designed, analysed
and interpreted data. K.H.A., K.M., D.A.K. and G.A.Y. wrote the article. D.A.K.,
K.M. and G.A.Y. provided critical intellectual content.
Additional information
How to cite this article: Flores-Otero, J. et al. Ligand-specific
endocytic dwell times control functional selectivity of the cannabinoid receptor 1. Nat. Commun.
5:4589 doi: 10.1038/ncomms5589 (2014).
Supplementary Figures
Supplementary Figures 1-4
Supplementary Movie 1
Surface SEP-CB1Rs quenching. Simultaneous dual fluorescence TIRF microscopy
series (10Hz) from a HEK cell co-expressing SEP-CB1R and RFP-β-arrestin-2
were incubated with 5 μM WIN 55,212-2 to induce receptor
clustering and endocytosis. Perfusion of MES pH5.5 resulted in a rapid
decrease in SEP-CB1R fluorescence.
Supplementary Movie 2
Imaging CB1Rs endocytosis by TIRF microscopy. Simultaneous dual fluorescence
TIRF microscopy series (0.3Hz) from a HEK cell co-expressing SEP-CB1R and
RFP-β-arrestin-2. Endocytosis was initiated with 5 μM WIN
55,212-2, resulting in receptor clustering, beta-arrestin recruitment and
endocytosis. Total running time= 30 minutes.
Authors: O B Goodman; J G Krupnick; F Santini; V V Gurevich; R B Penn; A W Gagnon; J H Keen; J L Benovic Journal: Nature Date: 1996-10-03 Impact factor: 49.962
Authors: Zara Y Weinberg; Amanda S Zajac; Tiffany Phan; Daniel J Shiwarski; Manojkumar A Puthenveedu Journal: Mol Pharmacol Date: 2017-02-02 Impact factor: 4.436
Authors: David R Janero; Suma Yaddanapudi; Nikolai Zvonok; Kumar V Subramanian; Vidyanand G Shukla; Edward Stahl; Lei Zhou; Dow Hurst; James Wager-Miller; Laura M Bohn; Patricia H Reggio; Ken Mackie; Alexandros Makriyannis Journal: ACS Chem Neurosci Date: 2015-05-29 Impact factor: 4.418